J Clin Oncol. 2006 Jan 1;24(1):45-51. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. Rustin GJ, Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom. grustin@nhs.net A definition for progression of ovarian cancer has been proposed based on either a confirmed doubling of CA-125 levels from the upper limit of normal or from the nadir level if levels are persistently elevated. Retrospectively, we determined whether the use of this CA-125 definition in a randomized trial would have shown the same magnitude of difference between the treatment arms as was shown when the standard progression definition was used. A retrospective analysis was performed on 680 patients in the Taxol Intergroup Trial with advanced epithelial ovarian carcinoma, of whom 628 were assessable according to CA-125. The date of progression according to clinical or radiologic criteria was compared with the date of progression according to CA-125. Of the 628 patients assessable for both definitions, 556 clinical or radiologic progressions were determined compared with 389 according to the CA-125 definition. There was a highly significant difference in the hazard of progression between the paclitaxel and cisplatin arm (TP) compared with the cyclophosphamide and cisplatin arm (CP) when either standard or CA-125 criteria were used to define progression (standard, P = .002; CA-125, P = .011). The hazard ratio of TP/CP over time was similar when comparing the different methods of defining progression. The results of this analysis show that the magnitude of the therapeutic benefit was similar whether CA-125 or standard criteria were used to define progression.
Please click on the required question. Thank
you for choosing to visit us. This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT. I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.Purpose:
Patients and
Methods:
Results:
Conclusion:
Reducing the Risks of Womens' Cancers.
Cancer of the Cervix.
Endometrial Cancer (Uterus)
Cancer of the Ovary.
The Treatment Of Womens' Cancers
Cancer of the Vulva, Vagina and Fallopian Tube
Breast Cancer
Web sites and Support Groups
- Introduction
- Abortion
- Amenorrhoea
- Birth Control
- Bladder Symptoms
- Cancer in Women
- What is cancer?
- Cancer Staging
- Prevalence
- Familial Cancer
- Symptoms, Signs, Diagnosis
- Prevention
- Screening
- Emotional Effects
- Counselling
- Personality and Outcome
- Holistic Approach
- Breast Cancer
- Ovarian Cancer
- Cervical Cancer
- Endometrial Cancer
- Vulva, Vagina, Fall.Tubes
- Treatments
- Mortality
- Support Groups
- Childbirth
- Children and Teenagers
- Diet / Weight Loss
- Dysmenorrhoea
- Endometriosis
- Fibroids
- HRT
- Hirsutism
- Hysterectomy
- Infections
- Infertility
- Medication Drugs
- Menopause
- Menorrhagia
- Miscarriage
- Painful Sex
- Pap Smear Test
- PCOS
- Pelvic Pain
- PMS
- Postpartum
- Pregnancy
- Self Esteem
- Sexual Problems
- Vaginal Discharge
- Vaginal Prolapse
- Vulval Symptoms
Underperforming Family Website?
This website
2womenshealth.com
is the
most popular personal website
in its category
1.5 million visitors annually.
The author has applied
his clinical and
scientific research experience
to
the application of techniques to
promote your web pages.
Visit
Now
Promote Your
Family Website
Improve Your Business Income
